Literature DB >> 21769596

Implementation and evaluation of a pharmacy-led thromboprophylaxis campaign in a community hospital.

Marie-Christine Bernier1, Karine Desjardins, Josée Filiatrault, Marc-André Sauriol, Josée Martineau, Edith Gilbert, Stéphanie Caron, Lyne Lalonde.   

Abstract

In hospitalized patients, venous thromboembolism (VTE) is an important cause of morbidity and mortality. Despite evidence demonstrating efficacy and safety of pharmacological thromboprophylaxis in the prevention of VTE, its use remains low. The aim of this study is to compare the incidence of use of thromboprophylaxis before and after a pharmacy-led thrombosis prevention campaign in medical patients hospitalized in a community hospital. A pharmacy-led multifaceted thromboprophylaxis campaign including continuing education activities for physicians and pharmacists and individualized academic detailing activities supported by clinical tools were implemented over an 8-week period. In a quasi-experimental study, the incidence of pharmacological thromboprophylaxis was evaluated using a retrospective chart review and compared before and after the campaign in medical patients at high and non-high risk of VTE as defined by the American College of Chest Physicians criteria. The medical charts of 461 patients were reviewed; 66 and 58 patients were at high-risk of VTE prior to and after the campaign, respectively. After the campaign, thromboprophylaxis ordering in high-risk patients increased from 15.2 to 43.1% (adjusted OR: 6.8; 95% CI: 2.5-18.0). Thromboprophylaxis ordering in non-high risk patients was 1.8% before the campaign and 6.0% after. This increase was not statistically significant (adjusted OR: 4.6; 95% CI: 1.0-20.4). The incidence of pharmacologic thromboprophylaxis in hospitalized medical patients at high-risk of VTE increased significantly after the campaign but remained sub-optimal. Longer or a different campaign may be needed to ensure long-term optimal thromboprophylaxis use.

Entities:  

Mesh:

Year:  2011        PMID: 21769596     DOI: 10.1007/s11239-011-0614-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  17 in total

1.  Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates.

Authors:  Jason M Stinnett; Robert Pendleton; Leanne Skordos; Michelle Wheeler; George M Rodgers
Journal:  Am J Hematol       Date:  2005-03       Impact factor: 10.047

2.  Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.

Authors:  H Halkin; J Goldberg; M Modan; B Modan
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

3.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

Authors:  M M Samama; A T Cohen; J Y Darmon; L Desjardins; A Eldor; C Janbon; A Leizorovicz; H Nguyen; C G Olsson; A G Turpie; N Weisslinger
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

4.  Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis.

Authors:  Christopher S King; Aaron B Holley; Jeffrey L Jackson; Andrew F Shorr; Lisa K Moores
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

5.  Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients.

Authors:  C Ibarra-Pérez; E Lau-Cortés; S Colmenero-Zubiate; N Arévila-Ceballos; J H Fong; R Sánchez-Martínez; M V Dominguez; J Elizalde-González
Journal:  Angiology       Date:  1988-06       Impact factor: 3.619

6.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 7.  Economic burden of venous thromboembolism in hospitalized patients.

Authors:  Paul P Dobesh
Journal:  Pharmacotherapy       Date:  2009-08       Impact factor: 4.705

8.  Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.

Authors:  Alain Leizorovicz; Alexander T Cohen; Alexander G G Turpie; Carl-Gustav Olsson; Paul T Vaitkus; Samuel Z Goldhaber
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

9.  Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.

Authors:  Susan R Kahn; Akbar Panju; William Geerts; Graham F Pineo; Louis Desjardins; Alexander G G Turpie; Stanislav Glezer; Lehana Thabane; Rolf J Sebaldt
Journal:  Thromb Res       Date:  2006-03-03       Impact factor: 3.944

10.  Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review.

Authors:  Sherali A Rahim; Akbar Panju; Menaka Pai; Jeffrey Ginsberg
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

View more
  4 in total

1.  Should residency projects involve more than one resident?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2014-01

2.  [Not Available].

Authors: 
Journal:  Can J Hosp Pharm       Date:  2014-01

3.  Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.

Authors:  Esin Aysel Kandemir; Aygin Bayraktar-Ekincioglu; Saadettin Kilickap
Journal:  Support Care Cancer       Date:  2020-08-10       Impact factor: 3.603

4.  Developing an Economic Case of Clinical Pharmacists' Interventions on Venous Thromboembolism Prophylaxis Through Service Evaluation.

Authors:  Eun Hee Lee; Victoria Bray; Robert Horne
Journal:  J Res Pharm Pract       Date:  2017 Apr-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.